Pneumococcie
The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study
In Ontario, pneumococcal conjugate vaccines (PCVs) have been sequentially introduced into the publicly funded childhood vaccination program since 2005. A 23-valent polysaccharide pneumococcal vaccine (PPV23) has been routinely recommended for adults aged 65 years and older since 1996. To determine the effect of herd immunity, we examined the epidemiology of invasive pneumococcal disease in adults aged 65 years and older.
Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older Interim Recommendation
The objective of this Statement Update is to provide evidence and interim recommendations for the use of PNEU-C-13 in immunocompetent adults over 65 years of age and to allow informed decision making in cases when PNEU-C-13 is being considered on an individual basis for use in this age group.
Vaccine coverage in Canadian children: Highlights from the 2013 childhood National Immunization Coverage Survey (cNICS)
The 2013 Childhood National Immunization Coverage Survey (cNICS) is the largest national-level immunization coverage survey ever carried out in Canada. Results from the survey showed that the majority of Canadian children are immunized against vaccine-preventable diseases, but there is room to improve in keeping vaccinations up to date.
Vaccine uptake in Canadian adults: results from the 2014 adult National Immunization Coverage Survey
The Adult National Immunization Coverage Survey (aNICS) constitutes an ongoing approach to measuring adult immunization coverage in Canada and monitoring progress towards national targets. The next aNICS cycle will take place in 2016. The Public Health Agency of Canada will continue to work to collaborate with provinces, territories and other stakeholders to improve immunization coverage assessment methodology. Public and professional education and outreach campaigns will also continue to promote the benefits and safety of immunization in Canada.
Adult pneumococcal immunization
Only 16.7% of Canadian adults (18 to 64 years of age) with chronic medical conditions are immunized against Streptococcus pneumoniae. The National Advisory Committee on Immunization has recently updated its guidelines about adults who qualify for immunization.
Le vaccin contre le pneumocoque
Identifie les différents types d’infections à pneumocoque (la méningite, la bactériémie, la pneumonie et l’otite moyenne aiguë) et suggère quand un enfant devrait recevoir le vaccin. Explique comment les maladies à pneumocoque se transmettent, et comment identifier si un enfant a une infection à pneumocoque.
Pneumococcal vaccine
Identifies the different types of pneumoccocal infections (meningitis, bacteremia, pneumonia, otitis media) and suggests when a child should receive the vaccine. Explains how pneumoccocal diseases are transmitted, and how to recognize if I child has a pneumoccocal infection.
Re-Immunization with Polysaccharide 23-Valent Pneumococcal Vaccine (Pneu-P-23 )
This statement will supplement previous pneumococcal statements and provide the evidence used to determine the optimal time between initial vaccination with polysaccharide 23-valent pneumococcal vaccine (Pneu-P-23) and subsequent booster doses to protect against invasive pneumococcal disease in those at highest risk for IPD.
Rethinking risk for pneumococcal disease in adults: the role of risk stacking
Using data from 3 private healthcare claims repositories, the researchers evaluated the incidence of pneumococcal disease among adults with US Advisory Committee on Immunization Practices (ACIP) defined at-risk conditions or rheumatoid arthritis, lupus, Crohn's disease, and neuromuscular disorder/seizures and those with traditional high-risk conditions. They observed that adults with ≥2 concurrent comorbid conditions had pneumococcal disease incidence rates that were as high as or higher than rates observed in those with traditional high-risk conditions.
Revaccination avec le vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23)
La présente déclaration complétera les déclarations précédentes sur le pneumocoque et fournira les données probantes utilisées pour déterminer la période optimale entre l’administration initiale du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) et les doses de rappel ultérieures afin de protéger les personnes à risque de pneumococcie invasive (PI).